argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
10 Février 2022 - 7:00AM
February 10, 2022Breda,
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that members of management will participate in a fireside chat at
the 11th Annual SVB Leerink Global Healthcare Conference on
Thursday, February 17, 2022 at 10:40 a.m. ET.
A live webcast of the presentation may be accessed on the
Investors section of the argenx website at argenx.com/investors. A
replay of the webcast will be available on the argenx website for
approximately 90 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the
lives of people suffering from severe autoimmune diseases.
Partnering with leading academic researchers through its Immunology
Innovation Program (IIP), argenx aims to translate immunology
breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx developed and is commercializing the
first-and-only approved neonatal Fc receptor (FcRn) blocker in the
U.S. and Japan. The Company is evaluating efgartigimod in multiple
serious autoimmune diseases and advancing several earlier stage
experimental medicines within its therapeutic franchises. For more
information, visit www.argenx.com and follow us
on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Kelsey Kirkkkirk@argenx.com
Joke Comijn (EU)jcomijn@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024